Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Citigroup Inc.

Citigroup Inc. increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 65.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,084 shares of the company’s stock after acquiring an additional 13,874 shares during the period. Citigroup Inc. owned about 0.12% of Krystal Biotech worth $6,386,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. EFG Asset Management North America Corp. lifted its position in shares of Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares in the last quarter. GAMMA Investing LLC boosted its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after acquiring an additional 94 shares in the last quarter. Arizona State Retirement System increased its position in shares of Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares during the period. Finally, Fiera Capital Corp raised its stake in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

KRYS has been the topic of several recent research reports. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Stifel Nicolaus boosted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $202.29.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $197.42 on Friday. The company has a market capitalization of $5.68 billion, a price-to-earnings ratio of 111.54 and a beta of 0.82. The firm’s fifty day moving average price is $180.49 and its 200 day moving average price is $183.75. Krystal Biotech, Inc. has a 12 month low of $100.78 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) earnings per share. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).